StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Provectus Biopharmaceuticals's free cash flow for the twelve months ending Dec 31, 2017 was -$10.38M. For fiscal 2017 it was -$10.38M. The highest annual figure on record is -$8.60M in fiscal 2009.

Annual free cash flow

PeriodPeriod endValueChange
FY2017Dec 31, 2017-$10.38M–
FY2015Dec 31, 2015-$17.42M–
FY2014Dec 31, 2014-$13.92M–
FY2013Dec 31, 2013-$9.90M–
FY2012Dec 31, 2012-$11.27M–
FY2011Dec 31, 2011-$17.21M–
FY2009Dec 31, 2009-$8.60M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2017Dec 31, 2017-$2.47M–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?